All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-04-22T14:25:50.000Z

Combining bispecific antibodies with daratumumab to treat relapsed/refractory MM

By Becky Gribbell, Erika Roa, Ella Dixon
Featured
María-Victoria Mateos
Apr 22, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

Bookmark this article

During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal antibodies to treat relapsed/refractory multiple myeloma?

Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM

Mateos begins by giving an overview of the bispecific antibodies, talquetamab and teclistamab. These antibodies have been investigated in combination with daratumumab in two clinical trials; Mateos provides a summary of the results of these trials, including the safety and efficacy data.

 

More about...
DaratumumabEMNEMN 2022Relapsed/refractory multiple myelomaT-cell engagersTalquetamabTeclistamab

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
27 votes - 6 days left ...

Related articles

Add bookmark

Teclistamab, a BCMA/CD3 bispecific antibody for patients with RRMM: Phase I MajesTEC-1 trial results

Multiple myeloma remains an incurable disease despite recent advances in treatment, and so patients may undergo multiple rounds of remission and...

Aug 13, 2021
Add bookmark

Teclistamab, a BCMA/CD3 bispecific antibody for patients with RRMM: Phase I MajesTEC-1 trial results

Multiple myeloma remains an incurable disease despite recent advances in treatment, and so patients...

Aug 13, 2021
Add bookmark

Talquetamab for relapsed/refractory multiple myeloma: Results from a phase I study

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated encouraging clinical responses in patients with multiple...

Jan 25, 2021
Add bookmark

Talquetamab for relapsed/refractory multiple myeloma: Results from a phase I study

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated encouraging...

Jan 25, 2021
Add bookmark

CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

Interview with Co-Chair María-Victoria Mateos on updates from this year's virtual ASCO Annual Meeting and EHA Annual Congress. We asked, CAR T-cell therapy or...

Aug 19, 2020
Add bookmark

CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

Interview with Co-Chair María-Victoria Mateos on updates from this year's virtual ASCO Annual Meeting and EHA...

Aug 19, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox